Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398632 · ClinicalTrials.gov registry record · Phase 4
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
A Phase 4 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00398632: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT00398632 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398632, a Phase 4 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs). The hypotheses of this study are that:1. subjects with major depression or dysthymia who are being treated with an SSRI and experiencing treatment-related sexual dysfunction will experience less sexual dysfunction if they are switched to duloxetine, and 2. they will experience either improved antidepressant response or no loss of antidepressant response.
Primary Outcome
The GCI-I score is a global clinical impression score regarding a patient's symptom severity change rated by the treating clinician. The score can be 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) or 7 (very much worse). In this study clinicians made ratings based on interviewing the patient and reviewing the patient's self ratings on the the Arizona Sexual Experiences Scale (ASEX). No formal cut point score
Interventions
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Why NCT00398632 stopped before completion
NCT00398632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Duloxetine is the first listed.
NCT00398632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00398632 about?
NCT00398632 is a clinical study titled "Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction". Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs). The hypotheses of this study are that:1. subjects with major depression or dysthymia who are being treated with an SSRI and experiencing treatment-related sexual dysfunction will experience less sexual dys...
What is the current status of trial NCT00398632?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2006-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00398632?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00398632?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00398632's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia